TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven incurable, metastatic, hormone-refractory adenocarcinoma of the prostate that is unlikely to respond to existing therapy~  * Evidence of tumor by MRI, CT scan, chest x-ray, or radionuclide scan~ * Stage D2~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* Hemoglobin at least 9 g/dL~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No known chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as severe chronic obstructive pulmonary disease~Other:~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* Not a high medical or psychiatric risk~* No concurrent nonmalignant systemic disease~* No active infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* At least 4 weeks since prior hormonal therapy (unless progression documented upon discontinuation of hormones)~* Concurrent corticosteroids allowed, if stable or decreasing for at least 2 months before study entry~Radiotherapy:~* At least 4 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agent allowed

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy~Exclusion Criteria:~* LDL-C levels \> 250 mg/dL (6.48 mmol/L)~* Triglycerides levels \> 350mg/dL (3.95 mmol/L)~* Conditions / situations such as:~  * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels~ * Active liver disease~ * High estimated risk of Coronary Heart Disease~ * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease~ * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive~* Pregnant or breast-feeding women,~* Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 25 mg/day AVE5530 (Type: EXPERIMENTAL): None
- 50 mg/day AVE5530 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Erenumab For Treatment of Hemicrania Continua

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Adults over the age of 18-66~* At least a 12 month history of hemicrania continua (unremitting subtype) according to International Classification of Headache Disorders, 3rd Edition (ICHD-3)1~* Previous or current complete response to indomethacin~* Stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment~Exclusion Criteria~* Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week~* Pregnant or lactating subjects~* Use of barbiturate or opioid \>6 days per month; history of chronic migraine~* History of previous trigeminal-autonomic cephalalgia~* History within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy)~* History of cranial nerve/rhizolysis~* Botulinumtoxin injection with previous 4 months~* Parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with Erenumab (Type: EXPERIMENTAL): Subjects diagnosed with hemicrania continua will receive single dose of Erenumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-80 years old;~2. Diagnosis of posterior circulation ischemic stroke;~3. Time from onset to treatment ≤6 hours;~4. NIHSS: 4-25;~5. Signed informed consent by patient self or legally authorized representatives.~Exclusion Criteria:~1. mRS≥2;~2. History of stroke within 3 months;~3. History of intracranial hemorrhage;~4. Suspected subarachnoid hemorrhage;~5. Intracranial tumour, vascular malformation or arterial aneurysm;~6. Major surgery within 1 month;~7. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;~8. Platelet count \< 105/mm3;~9. Heparin therapy or oral anticoagulation therapy within 48 hours;~10. Abnormal APTT;~11. Thrombin or Xa factor inhibitor;~12. Severe disease with a life expectancy of less than 3 months;~13. Blood glucose \< 50 mg/dL (2.7mmol/L);~14. Patients who have received any other investigational drug or device within 3 months;~15. Pregnancy;~16. Researchers consider patients inappropriate to participate in the registry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Argatroban combined with rt-PA (Type: EXPERIMENTAL): None
- rt-PA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. males and females, aged 18 to 65, with headaches longer than 30 minutes per day for at least 15 days per month (28 days) meeting ICHD-IIR criteria for chronic migraine. Subjects must have headaches at least 8 days per month which are alleviated with triptans or ergots AND/OR which have at least 1 migrainous feature (unilaterality of headache or pain more prominent on 1 side of the head, throbbing, nausea, vomiting, photophobia, phonophobia, increased pain with physical exertion or avoidance of exertion)~2. subjects willing and able to perform all study-related measures including accurately completing study diaries and instruments, maintaining stable doses of headache preventative medications, completing study visits and obtaining blood testing as indicated.~3. women of childbearing potential must use an acceptable method of birth control for the duration of the study (oral contraceptives, IUD, injectable or intravaginal contraception or barrier methods combined with spermicide)~Exclusion Criteria:~1. subjects \<18 and \>65 years of age~2. pregnancy or attempted pregnancy during the study~3. nursing females~4. psychiatric condition which, in the investigator's opinion will influence trial safety or data collection~5. new daily persistent headache, hemicrania continua, chronic tension-type headache or cluster headache diagnoses.~6. headache suspicious for and not investigated to rule out secondary headache disorder~7. angle closure glaucoma~8. urinary retention~9. hepatic impairment felt by the investigator to interfere with study safety (as determined from history and/or prerequisite liver function testing within 1 year of study enrollment)~10. within 14 days of MAO inhibitor use or discontinuation~11. known hypersensitivity to cyclobenzaprine hydrochloride or any component of Amrix formulation~12. concomitant tramadol or tricyclic antidepressant use~13. history of myocardial infarction or congestive heart failure~14. hyperthyroidism~15. new start of daily preventative medication (which may influence headaches) less than 2 months preceding enrollment~16. dosage change or discontinuation of daily preventative medication (which may influence headaches) within 1 month of trial enrollment -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- cyclobenzaprine hydrochloride (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Programs of Reeducation for Urinary Incontinence in Woman

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients more than 18 years old and less than 75 years~* Patients presenting an urinary incontinence of effort or mixed symptomatic associated with a pelvic statics disorder~* Patients with a perineale reeducation prescription~* Patients affiliated to a national insurance scheme or benefiting from such a program~* Patients having given her written consent form~Exclusion Criteria:~* Nulliparous woman~* Patients already operated for their incontinence~* Patients with a prolapse of higher level at the stage II of the classification POP-Q (Pelvic Organ Prolapse Quantification)~* Pregnant women~* Patients presenting an associated anal incontinence,~* Patients presenting a cancellation (section of marrow, syringomyelia for example) or an inversion of perineum control~* Patients having given birth less than 6 months before the care~* Patients having benefited from a pelvi-périnéale reeducation in the previous 12 months,~* Patients presenting psychiatric disease~* Patients presenting a vaginismus,~* Patients presenting a contraindication to the practice of the electrostimulation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Reference method
- Group B (Type: EXPERIMENTAL): CMP ® method (Knowledge and Control of Perineum)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: VitalScan MCG Rule-out Multi-centre Pivotal Study - US

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient presents to the ED with chest pain syndrome of suspected cardiac origin (i.e. symptoms consistent with ACS)~* 18+ year old male or female~* Patient is willing and able to give written informed consent~Exclusion Criteria:~* ST-segment Elevation MI (STEMI)~* Clear non-ischemic cause for symptoms (e.g. trauma)~* Hemodynamic instability on admission (e.g. BP\>220mmHg systolic \& \>110mmHg diastolic, \<80mmHg systolic \& \<40mmHg diastolic, HR\>160bpm)~* Ventricular tachycardia or fibrillation that cannot be treated effectively~* Atrial fibrillation~* Thoracic metal implants~* Pacemaker or internal defibrillator~* Pregnancy (if after 20-week period)\* or lactation~* Patient unable to lie down (i.e. supine position) or stay still on the examination bed~* Patient unable to understand the informed consent process and/or has a poor understanding of English (e.g. English- speaking relative/translator not available)~* Patient unable to comply with the requirements of the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chest pain patients presenting to the ED (Type: None): All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-diabetic subjects with asthma, or COPD. Non-smokers or smokers quit at least 6 months prior to enrollment. BMI \<= 35 kg/m2. Fasting blood glucose \<= 125 mg/dL.~Exclusion Criteria:~* pulmonary disorder other than asthma or COPD. Upper respiratory within previous 4 weeks. Significant exacerbation of asthma or COPD symptoms. Hospitalization for asthma or COPD within previous 3 months. Clinically significant medical condition. Current medications interfering with glucose metabolism.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Dance 501 (Type: EXPERIMENTAL): Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
- Insulin Lispro (Type: ACTIVE_COMPARATOR): Insulin Lispro (Humalog®) will be administered by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Remote Electronically Delivered Integrated Care Pathway: A Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 13-18 years old at baseline~* Mood and Feelings Questionnaire - Childhood, long version (MFQ) score of ≥22~* Diagnosis of Major Depressive Disorder by impression from the referring psychiatrist and confirmed using the KSADS~* Internet access at home~* Access to a smartphone for personal and private use, with an associated standard data plan (ie. greater than or equal to 500 MB/month)~* Able to speak and read English fluently~Exclusion Criteria:~* Individuals that arecurrently receiving structured psychotherapy~* Clinically significant suicidal ideation that is defined as 'imminent intent' or attempted suicide in the past 6 months~* Co-morbid diagnosis of borderline personality disorder (as assessed by the Childhood Interview for Borderline Personality Disorder) (Zanarini, 2003), schizophrenia, bipolar disorder, moderate-to-severe eating disorder, obsessive compulsive disorder and/or severe alcohol/substance use disorder in the past 3 months~* Youth with known or clinically suspected intellectual disability or autism spectrum disorder~* Youth who are not able to provide informed consent for any other reason

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Remote Electronically Delivered Integrated Care Pathway (ICP) (Type: EXPERIMENTAL): The remote electronically-delivered ICP (also known as eCARIBOU) will consist of psychiatry appointments through telemedicine every 4 weeks over 16 weeks, where the youth is at home. Prior to these appointments, measures (i.e., Mood and Feelings Questionnaire - MFQ) will be sent to the youth to be completed. Change in measure scores will be reviewed collaboratively between the psychiatrist and the youth to assist in making treatment decisions. The medication algorithm in the in-person ICP will be used to guide these decisions. The psychiatrist will also administer the Columbia Suicide Severity Rating Scale (C-SSRS) at each telepsychiatry appointment to monitor risk. Concurrently, youth will be offered internet-based Cognitive Behavioural Therapy (iCBT) and health-coaching via text.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FLX475 in Combination With Ipilimumab in Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IV or unresectable Stage III advanced melanoma~* Prior treatment with at least 2 months of anti-PD-(L)1 agent~* Measurable disease at baseline~* Tumor available for biopsy~Exclusion Criteria:~* History of allergy or severe hypersensitivity to biologic agents~* History of Grade 3-4 immune-related adverse events leading to discontinuation of prior immunotherapy~* Prior treatment with ipilimumab or other (cytotoxic T-lymphocyte-associated antigen 4) CTLA-4 antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLX475 and ipilimumab combination therapy (Type: EXPERIMENTAL): Participants received FLX475 tablets orally and ipilimumab by IV infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Patient has a diagnosis of primary Type I or II achalasia.~* Patient has no contraindications to the performance of the baseline and postdose HRIM procedures per Investigator discretion.~Key Exclusion Criteria:~* Patient has had any prior esophageal, periesophageal, or gastric surgery, or treatment with sclerosing agent.~* More than 1 pneumatic dilation procedure to a diameter of \> 2 cm in their lifetime.~* Pneumatic dilation procedure to a diameter of \> 2 cm within 1 year prior to randomization. Prior bougie dilation(s) or pneumatic dilation(s) ≤ 2 cm are allowed.~* Prior esophageal injection of botulinum toxin (Botox) within 6 months prior to randomization or more than 2 esophageal Botox injection procedures in their lifetime.~* Patients with malignant or premalignant esophageal lesions.~* Patient has taken any drug that can affect gastrointestinal (GI) motility in the 72 hours before check-in through discharge from the clinic.~Other inclusion and exclusion criteria specified in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IW-1701 (Type: EXPERIMENTAL): Single 5-mg dose of IW-1701 administered orally
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo administered orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any adult patient starting capecitabine-containing chemotherapy~* Has never had capecitabine before~* Performance status 0-2 using the ECOG classification~* Life expectancy more than 6 months~* Agreed to stop any vitamin supplements, apart from vitamin D.~* Liver function studies including AST/ALT within 3x upper limit of normal~* Signed informed consent must be obtained from participating individuals

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin B6 (Type: EXPERIMENTAL): patient receiving xeloda and vitamin B6
- 2 placebo (Type: PLACEBO_COMPARATOR): patient receiving xeloda and placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues